Clinical Experience with Gefitinib in Indian Patients
Authors:
- Purvish ParikhPPPurvish Parikh
- Alex Yuang-Chi ChangACAlex Yuang-Chi Chang
- Shona NagSNShona Nag
- Raghunadharao DigumartiRDRaghunadharao Digumarti
- Gouri Shankar BhattacharyyaGBGouri Shankar Bhattacharyya
- Dinesh Chandra DovalDDDinesh Chandra Doval
- Govind BabuGBGovind Babu
- Raju Titus ChackoRCRaju Titus Chacko
- Suresh AdvaniSASuresh Advani
- Anantbhushan RanadeARAnantbhushan Ranade
- Shyam AggarwalSAShyam Aggarwal
- Ramesh JagannathanRJRamesh Jagannathan
- 1 April 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (4) , 380-385
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancerCurrent Medical Research and Opinion, 2006
- Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroyEuropean Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North AmericaLung Cancer, 2005
- 71 Central nervous toxicity of gefitinib in adultLung Cancer, 2005
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI: Journal of the National Cancer Institute, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern IndiaInternational Journal of Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003